3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Ovarian Neoplasms
33
Breast Neoplasms
26
Triple Negative Breast Neoplasms
17
Prostatic Neoplasms
16
Fallopian Tube Neoplasms
11
Neoplasms
9
Fanconi Anemia, Complementation Group D1
7
Endometrial Neoplasms
7
Pancreatic Neoplasms
6
Glioma
6
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Small Cell Lung Carcinoma
5
Sarcoma
5
Neoplasm Metastasis
5
Cholangiocarcinoma
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Lymphoma, Non-Hodgkin
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Osteosarcoma
3
Lung Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Carcinosarcoma
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Interventions
Trastuzumab
5
Carboplatin
4
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
olaparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled